The OTEZLA® international website

This site is intended for healthcare professionals outside the U.S.

UNMET NEEDS REMAIN IN TREATMENT1

Patients are dissatisfied with traditional oral therapies1

The MAPP survey revealed unmet needs in treatment:

Data graphs from the MAPP survey showing the percentage of patients who are dissatisfied with traditional oral therapies for treating psoriatic arthritis.

*Subset of all patients surveyed. Overall, 24% of all patients said they had been prescribed a traditional oral medication for their disease (eg, cyclosporine, methotrexate, acitretin, or fumaric acid esters) at some point since their diagnosis; of these, 43% were receiving therapy and 57% had discontinued use.

  • 66% of psoriatic arthritis patients report comorbidities, which may contribute to difficulties in treatment1

Patients who discontinued traditional oral therapies did so primarily due to concerns about efficacy, safety, and tolerability1

THE HETEROGENEITY OF PSORIATIC ARTHRITIS IS A MAJOR CHALLENGE IN THE TREATMENT OF DISEASE

Multiple manifestations impact physical function and contribute substantially to disease burden2-5

  • Enthesitis is present in up to 78% of patients and nearly half (48%) of patients report dactylitis, both of which are associated with higher levels of physical impairment2-4
  • Extra-articular domains such as skin and nail psoriasis constitute nearly half of patient-reported burden of disease5
  • There are 6 key domains recognized in psoriatic arthritis: Peripheral arthritis, enthesitis, dactylitis, skin, nail, and axial disease6

Up to 50% of psoriatic arthritis patients have an oligoarticular form of the disease7-9

  • Oligoarthritis is characterized by fewer affected joints and less erosive disease9
  • Despite being a less-progressive disease, patients with oligoarthritis report high disease burden10

Treatment for psoriatic arthritis should address as many of the 6 key
domains as possible, while balancing safety considerations6

Consider oral OTEZLA for your patients with psoriatic arthritis11,a
 
OTEZLA
Methotrexate
Sulfasolazine
Leflunomide
PsA - specific evidence
Effectiveness in multiple PsA domains, including dactylitis and enthesitistable-checktable-crosstable-crosstable-cross
Evidence of long-term efficacytable-checktable-crosstable-crosstable-cross
Proven long-term safety profiletable-checktable-crosstable-crosstable-cross
Other considerations
No label-required laboratory prescreening or ongoing monitoring*table-checktable-crosstable-crosstable-cross
Warnings and precautions
  • - Diarrhea
  • - Nausea
  • - Vomiting
  • - Psychiatric disorders
  • - Severe renal impairment
  • - Pregnancy
  • - Underweight patients
  • - Lactose content
  • - Diabetes
  • - Tuberculosis
  • - Hepatitis B
  • - Hepatitis C
  • - Shingles
  • - Liver disease
  • - Kidney disease
  • - Lung function
  • - Severely overweight
  • - Ascites
  • - Pleural effusions
  • - Dehydration
  • - Pregnancy
  • - Breastfeeding
  • - Severe allergy
  • - Bronchial asthma
  • - Hemolytic anemia
  • - Folic acid deficiency
  • - Kidney stones
  • - Steven Johnson syndrome
  • - Toxic epidermal
  • - Necrolysis
  • - Inflammation of the lung
  • - Tuberculosis
  • - Fathering a child
  • - Serious allergic reactions/DRESS
  • - Increased chance of severe infection

aProducts that are available as generic formulations are referred to by the active compound name.

*Regular monitoring is recommended for patients who are underweight at the start of treatment.

Nearly two-thirds of patients on stable conventional DMARDs
continue to have disease activity, suggesting that a majority of
patients may benefit from treatment modification12†

Observational, cross-sectional study (N = 152) conducted at 2 sites in Amsterdam involving patients with psoriatic arthritis on current or previous conventional DMARD, such as methotrexate or leflunomide, or TNF-inhibitor. Disease activity was defined by the treating rheumatologist (an answer of YES to the question: Do you think there is remaining disease activity in this patient, despite current treatment regimen?) based on physical examination at a routine clinical visit and collected outcome measures (VAS-PhysGlobal, VAS-PhysSkin, and BASDAI).

BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; DMARD, disease-modifying antirheumatic drug; DRESS, Drug Reaction with Eosinophilia and Systemic Symptoms; MAPP, Multinational Assessment of Psoriasis and Psoriatic Arthritis survey; PsA, psoriatic arthritis; TNF, tumor necrosis factor; VAS, visual analog scale.

References:

  1. Lebwohl MG, Bachelez H, Barker J, et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol. 2014;70(5):871-881.
  2. Orbai AM, Weitz J, Siegel EL, et al. Systemic review of treatment effectiveness and outcome measures for enthesitis in psoriatic arthritis. J Rheumatol. 2014;41(11):2290-2294.
  3. Brockbank JE, Stein M, Schentag CT, Gladman DD. Dactylitis in psoriatic arthritis: a marker for disease severity? Ann Rheum Dis. 2005;64(2):188-190.
  4. Kavanaugh A, Helliwell P, Ritchlin CT. Psoriatic arthritis and burden of disease: patient perspectives from the population-based multinational assessment of psoriasis and psoriatic arthritis (MAPP) survey. Rheumatol Ther. 2016;3(1):91-102.
  5. Dandorfer SW, Rech J, Manger B, Schett G, Englbrecht M. Differences in the patient’s and the physician’s perspective of disease in psoriatic arthritis. Semin Arthritis Rheum. 2012;42(1):32-41.
  6. Coates LC, Kavanaugh A, Mease PJ, et al. Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol. 2016;68(5):1060-1071.
  7. Coates LC, FitzGerald O, Gladman DD, et al. Reduced joint counts misclassify patients with oligoarticular psoriatic arthritis and miss significant numbers of patients with active disease. Arthritis Rheum. 2013;65(6):1504-1509.
  8. Lindqvist UR, Alenius G, Husmark T, et al. The Swedish early psoriatic arthritis register–2-year followup: a comparison with early rheumatoid arthritis. J Rheumatol. 2008;35(4):668-673.
  9. Nossent JC, Gran JT. Epidemiological and clinical characteristics of psoriatic arthritis in northern Norway. Scand J Rheumatol. 2009;38(4):251-255.
  10. Huscher D, Albrecht K, Bischoff S, et al. Patients with psoriatic arthritis and oligoarthritic subtype report higher disease burden than patients with a polyarthritic pattern–data from the German Collaborative Arthritis Centres. Presented at the ACR/ARHP Annual Meeting. November 6-11, 2015; San Francisco, CA.
  11. Data on file, Amgen Inc.
  12. Van Mens L, van de Sande MGH, Fluri IA, Atiqi S, van Kuijk AWR, Baeten DLP. Residual disease activity and treatment adjustments in psoriatic arthritis in current clinical practice. Arthritis Res Ther. 2017;19(1):226.
You are leaving the OTEZLA® (apremilast) website
Do you wish to leave this site?
OTEZLA International Websites
OTEZLA is approved in 54 countries*
  • United States

  • Canada

  • Australia

  • Israel

  • Switzerland

  • New Zealand

  • Austria

  • Belgium

  • Bulgaria

  • Croatia

  • Republic of Cyprus

  • Czech Republic

  • Denmark

  • Estonia

  • Finland

  • France

  • Germany

  • Greece

  • Hungary

  • Ireland

  • Italy

  • Latvia

  • Lithuania

  • Luxembourg

  • Malta

  • Netherlands

  • Poland

  • Portugal

  • Romania

  • Slovakia

  • Slovenia

  • Singapore

  • Spain

  • Sweden

  • United Kingdom

  • Norway

  • Iceland

  • Liechtenstein

  • Russia

  • Japan

  • Hong Kong

  • Kuwait

  • Taiwan

  • UAE

  • South Korea

  • Thailand

  • Lebanon

  • Qatar

  • Argentina

  • Mexico

  • Brazil

  • Malaysia

  • Oman

  • Saudi Arabia

On November 21, 2019, Amgen acquired from Celgene Corporation the worldwide rights to Otezla® (apremilast).

Effective November 21, 2019, refer to the Amgen's Terms of Use relating to the access of Amgen websites, applications and digital services and Privacy Statement concerning the collection and use of your personal information.

For information collected by Celgene prior to November 21, 2019, refer to Celgene's Terms of Use and Privacy Policy.